TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9752814

Group type: EXPERIMENTAL
Intervention: Expedited surgery (planned to take place within 6 weeks)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Routine surgery (routine waiting time, 7-12 months)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Expedited surgery
Number of subjects: 208
Study: 8141577

Group type: EXPERIMENTAL
Intervention: Foscarnet induction treatment
Number of subjects: 65
Study: 3125973

Group type: EXPERIMENTAL
Intervention: 50 mg thymostimulin (TS) i.m. daily for 35 days (G1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 50 mg thymostimulin (TS) i.m. every other day for 35 days (G2)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No treatment (G3)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Thymostimulin maintenance therapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: In vitro assessment of IL-2 and IFN-gamma synthesis in TS-treated patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Thymostimulin treatment
Number of subjects: 19
Study: 30597771

Group type: EXPERIMENTAL
Intervention: PF-04447943 25 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28202779

Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet (FMD) for 5 consecutive days per month for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unrestricted diet for 3 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Post hoc analysis of both FMD arms
Number of subjects: 100
Study: 26548737

Group type: COMPARATOR
Intervention: Typical chiropractic care only (manual therapy and exercises)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Typical chiropractic care with daily home use of the self-acupressure pillow (SAP)
Number of subjects: 34
Study: 23036940

Group type: EXPERIMENTAL
Intervention: Total activity minutes/week (AM)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Walking minutes/week (WM)
Number of subjects: 301
Study: 21625929

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Goserelin and Tamoxifen (combined)
Number of subjects: 927
Study: 18452778

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy (switched from UFH/ENOX)
Number of subjects: 4215

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy (naive to antithrombin therapy)
Number of subjects: 4215

Group type: COMPARATOR
Intervention: UFH/ENOX plus GP IIb/IIIa inhibitor (consistent therapy)
Number of subjects: 4215

Group type: COMPARATOR
Intervention: UFH/ENOX plus GP IIb/IIIa inhibitor (naive patients)
Number of subjects: 4215
Study: 17022864

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin
Number of subjects: 2959

Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 2959
Study: 12748969

Group type: EXPERIMENTAL
Intervention: Organized mammography screening
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: High perceived susceptibility (PS)
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: False positive screening finding
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE)
Number of subjects: 1942
Study: 11074742

Group type: EXPERIMENTAL
Intervention: Nicotine inhaler plus nicotine patch (delivering 15 mg of nicotine per 16 hours) for 6 weeks, then inhaler plus placebo patch for 6 weeks, then inhaler alone for 14 weeks
Number of subjects: 400

Group type: COMPARATOR
Intervention: Nicotine inhaler plus placebo patch for 12 weeks, then inhaler for 14 weeks
Number of subjects: 400
Study: 9051945

Group type: EXPERIMENTAL
Intervention: Alert Toothbrush
Number of subjects: 0
Study: 1395118

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study: 2866966

Group type: EXPERIMENTAL
Intervention: Indenolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol and Atenolol (Control Beta-blockers)
Number of subjects: 6
Study: 30657353

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 2226

Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 2226

Group type: EXPERIMENTAL
Intervention: Prediction-based treatment
Number of subjects: 2226

Group type: COMPARATOR
Intervention: Monochemotherapy
Number of subjects: 2226
Study: 28482405

Group type: EXPERIMENTAL
Intervention: Pegylated interferon α‐2b (Y shape, 40 kD) injection (180 µg/week) combined with ribavirin
Number of subjects: 561

Group type: COMPARATOR
Intervention: Standard-dose Peg‐IFN‐α‐2a combined with ribavirin
Number of subjects: 561
Study: 25846329

Group type: EXPERIMENTAL
Intervention: Cannabis users (n=46)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 116
Study: 25064421

Group type: EXPERIMENTAL
Intervention: STAGE‐12 therapy (high exposure, n=158)
Number of subjects: 234

Group type: COMPARATOR
Intervention: TAU alone (n=76)
Number of subjects: 234
Study: 21194910

Group type: EXPERIMENTAL
Intervention: Vitamin D2 100,000 units orally at baseline
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 20003299

Group type: EXPERIMENTAL
Intervention: OSTEOPOROSIS CHOICE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 0
Study: 16982815

Group type: EXPERIMENTAL
Intervention: Flow rate of 8 mL/sec
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flow rate of 4 mL/sec
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flow rate of 8 mL/sec with individualized scan delay
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flow rate of 4 mL/sec with fixed scan delay
Number of subjects: 40
Study: 14605513

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise (LEX, n=18)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (HEX, n=15)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 43
Study: 11103232

Group type: EXPERIMENTAL
Intervention: Combination of CDDP and 5-FU with chemo- and radiotherapy
Number of subjects: 0
Study: 8882105

Group type: EXPERIMENTAL
Intervention: Topical 4% lidocaine with antibiotic drops
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo with antibiotic drops
Number of subjects: 122
Study: 1433853

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study: 4011356

Group type: EXPERIMENTAL
Intervention: Comprehensive program with mock-up demonstration, written handouts, physician's orders for demonstration and discharge in a car seat
Number of subjects: 129

Group type: COMPARATOR
Intervention: Regular hospital program
Number of subjects: 129
Study: 30720530

Group type: EXPERIMENTAL
Intervention: Hands-on group (11 hours of hands-on massage practice)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hands-on group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Online-only group
Number of subjects: 20
Study: 28745941

Group type: EXPERIMENTAL
Intervention: Remote management care (including online patient portals, e‐mails, follow‐up phone calls, home health devices)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Remote management care
Number of subjects: 77
Study: 27487914

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration + hemophagocytic lymphohistiocytosis-2004 group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hemophagocytic lymphohistiocytosis-2004 group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration
Number of subjects: 33
Study: 23642962

Group type: EXPERIMENTAL
Intervention: Skin Damage and Severity Index (SDASI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Three different grades of infill materials
Number of subjects: 9
Study: 22072741

Group type: EXPERIMENTAL
Intervention: 1 mg zoledronate
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 2.5 mg zoledronate
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5 mg zoledronate
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: zoledronate (all doses)
Number of subjects: 180

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study: 20487050

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg
Number of subjects: 786

Group type: COMPARATOR
Intervention: atorvastatin 40 mg
Number of subjects: 786

Group type: COMPARATOR
Intervention: rosuvastatin 5 or 10 mg
Number of subjects: 786
Study: 18579811

Group type: EXPERIMENTAL
Intervention: 10 mg of oral rivaroxaban once daily
Number of subjects: 4541

Group type: COMPARATOR
Intervention: 40 mg of enoxaparin subcutaneously once daily
Number of subjects: 4541
Study: 16049380

Group type: EXPERIMENTAL
Intervention: EASI plus high dose oxytocin
Number of subjects: 151

Group type: COMPARATOR
Intervention: PGE2 gel
Number of subjects: 151
Study: 12444817

Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 to 80 mg/day (N = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (N = 30)
Number of subjects: 60
Study: 10638387

Group type: EXPERIMENTAL
Intervention: Paracetamol 10 mg/kg thrice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg thrice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nimesulide 2.5 mg/kg twice daily for 5 days
Number of subjects: 90
Study: 7569731

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFAs) supplementation, 4 g per day for 6 months
Number of subjects: 601

Group type: COMPARATOR
Intervention: Control group (no n-3 PUFA supplementation)
Number of subjects: 601
Study: 1940932

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg three times daily for 10 days starting on the first postoperative day
Number of subjects: 200

Group type: COMPARATOR
Intervention: No prophylactic treatment
Number of subjects: 200
Study: 6266028

Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin, 5000 units (Ul) 2 hours and 30 minutes before surgery then every 12 hours for 15 days (Protocol A)
Number of subjects: 2420

Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin, same dose and duration starting 24 to 72 hours after surgery (Protocol B)
Number of subjects: 2420

Group type: COMPARATOR
Intervention: No anticoagulant treatment (Protocol O)
Number of subjects: 2420
Study: 30863894

Group type: EXPERIMENTAL
Intervention: Medium dose soy drink (35 mg/day isoflavones) for 12 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low dose soy drink (10 mg/day isoflavones) for 12 weeks
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: High dose soy drink (60 mg/day isoflavones) for 12 weeks
Number of subjects: 101
Study: 29722251

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IPC-arm)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Local ischemic preconditioning (IPC-leg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: SHAM treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IPC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Local ischemic preconditioning (IPC)
Number of subjects: 12
Study: 28602039

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study: 25644485

Group type: EXPERIMENTAL
Intervention: SMART technique (Stapled Mesh stomA Reinforcement Technique)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (stoma resiting without mesh reinforcement)
Number of subjects: 22
Study: 22463392

Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning during transport to hospital
Number of subjects: 0
Study: 21251813

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (n=79)
Number of subjects: 162

Group type: COMPARATOR
Intervention: 3-weekly docetaxel (n=77)
Number of subjects: 162
Study: 19703948

Group type: EXPERIMENTAL
Intervention: Vulnamin gel with elastocompression
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inert gel vehicle with elastocompression
Number of subjects: 30
Study: 17466227

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 2445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2445
Study: 12731679

Group type: EXPERIMENTAL
Intervention: TCU Cognitive Skills Module (CSM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 10496523

Group type: EXPERIMENTAL
Intervention: Single-gland proliferation (adenomas)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Multiple-gland proliferation (primary hyperparathyroidism)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Secondary hyperparathyroidism
Number of subjects: 67
Study: 8622022

Group type: EXPERIMENTAL
Intervention: CEF chemotherapy (first-line treatment)
Number of subjects: 326

Group type: COMPARATOR
Intervention: CMF-based adjuvant chemotherapy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Anthracycline-based adjuvant chemotherapy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Not receiving adjuvant chemotherapy
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 326
Study: 1751940

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 181

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 181
Study: 7326852

Group type: EXPERIMENTAL
Intervention: 40 micrograms of triiodothyronine (T3) daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31256261

Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bolus intermittent furosemide
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 80
Study: 30760421

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 129
Study: 28300431

Group type: EXPERIMENTAL
Intervention: Honest response condition
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Faking-good response condition
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Reproduce response condition
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Instructed faking (faking-good)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Applicants' faking behavior
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: General faking behavior
Number of subjects: 243
Study: 26215651

Group type: EXPERIMENTAL
Intervention: Living well with Asthma (online self-management resource)
Number of subjects: 10
Study: 24046400

Group type: EXPERIMENTAL
Intervention: Diluent containing 0.30 µg of 25(OH)D3
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Diluent containing 0.60 µg of 25(OH)D3
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Diluent containing 1.20 µg of 25(OH)D3
Number of subjects: 61

Group type: COMPARATOR
Intervention: Noninjected controls
Number of subjects: 61

Group type: COMPARATOR
Intervention: Diluent-injected controls
Number of subjects: 61
Study: 21492164

Group type: EXPERIMENTAL
Intervention: Oltipraz 60 mg bid for 24 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oltipraz 90 mg qd for 24 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 18646345

Group type: EXPERIMENTAL
Intervention: Culturally tailored group educational program including a video and Q&A session with an African American physician
Number of subjects: 430

Group type: COMPARATOR
Intervention: Delayed intervention (crossover design)
Number of subjects: 430
Study: 16472330

Group type: EXPERIMENTAL
Intervention: rizatriptan 10-mg wafer
Number of subjects: 372
Study: 15658651

Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Pill (LDP) plus conventional therapy (Gliquidone or insulin) for 3 months
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional therapy (Gliquidone or insulin)
Number of subjects: 72
Study: 10027034

Group type: EXPERIMENTAL
Intervention: 10% lidocaine aerosol (2.5-4.7 mg kg-1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 44
Study: 7628183

Group type: EXPERIMENTAL
Intervention: Zifrosilone 10 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Zifrosilone 300 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Zifrosilone doses > or = 200 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 16296699

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7018557

Group type: EXPERIMENTAL
Intervention: 15 mg oestriol gel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mg PGF2 alpha gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: gel alone (control)
Number of subjects: 40
Study: 31154425

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 885
Study: 30010353

Group type: EXPERIMENTAL
Intervention: Tension Tamer (TT) guided BAM sessions for 5-, 10-, or 15-min intervals twice daily over 6 months
Number of subjects: 64
Study: 27657471

Group type: EXPERIMENTAL
Intervention: Nicorandil (5mg thrice daily for 12 weeks)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Standard therapy plus nicorandil
Number of subjects: 402

Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 402
Study: 24767094

Group type: EXPERIMENTAL
Intervention: Higher volume of whole blood (30 ml/kg; Tx30)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard volume of whole blood (20 ml/kg; Tx20)
Number of subjects: 160
Study: 22218843

Group type: EXPERIMENTAL
Intervention: Montelukast (4 mg oral, 12-week treatment)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (look-alike, 12-week treatment)
Number of subjects: 300
Study: 21055113

Group type: EXPERIMENTAL
Intervention: Continuous irrigation with simple drainage (Arm A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Simple drainage only (Arm B)
Number of subjects: 74
Study: 18318169

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emoxipin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16255449

Group type: EXPERIMENTAL
Intervention: Quality of life and psychological variables in primary care studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical and physical activity variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health and functional status in residential care for the elderly
Number of subjects: 0
Study: 12070194

Group type: EXPERIMENTAL
Intervention: Fexofenadine, zileuton, and nedocromil sodium
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 10188719

Group type: EXPERIMENTAL
Intervention: Low levels of coffee intake
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: High levels of coffee intake
Number of subjects: 2403

Group type: COMPARATOR
Intervention: One cup of coffee per day or less
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: High levels of water intake
Number of subjects: 2403
Study: 7594336

Group type: EXPERIMENTAL
Intervention: lansoprazole (30 mg/day)
Number of subjects: 18
Study: 31246258

Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care management control condition
Number of subjects: 0
Study: 31144445

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 units/mL (Gla‐300)
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Both Gla‐300 and IDeg
Number of subjects: 638
Study: 28418213

Group type: EXPERIMENTAL
Intervention: Lidocaine (0.25, 0.50, 1.0 or 10 mg/mL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 52
Study: 25486090

Group type: EXPERIMENTAL
Intervention: 0.8ng/kg LPS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.6ng/kg LPS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23576050

Group type: EXPERIMENTAL
Intervention: Sodium claims (disease risk reduction, function, and nutrient-content claims)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Taste control claim
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Hypertension status (hypertensives vs normotensives)
Number of subjects: 506
Study: 21595743

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 20 mg/day for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anti-TNF (adalimumab, Humira®) 40 mg s.c. single dose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19412143

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 48
Study: 17242700

Group type: EXPERIMENTAL
Intervention: p16(INK4a) negative tumours
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: p16(INK4a) positive tumours (intermediate expression)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High pRb expression
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High pRb expression in optimally debulked patients (n=82)
Number of subjects: 300
Study: 15052436

Group type: EXPERIMENTAL
Intervention: Mechanically stapled anastomoses
Number of subjects: 187

Group type: COMPARATOR
Intervention: Hand-sutured anastomoses
Number of subjects: 187
Study: 11679026

Group type: EXPERIMENTAL
Intervention: Passiflora extract 45 drops/day plus placebo tablet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oxazepam 30 mg/day plus placebo drops
Number of subjects: 36
Study: 9456071

Group type: EXPERIMENTAL
Intervention: Active substance provocation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7889022

Group type: COMPARATOR
Intervention: Haldol Decanoas (reference product)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Injectable haloperidol decanoate 141 mg/ml (test product)
Number of subjects: 15
Study: 3251495

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 8
Study: 30544411

Group type: EXPERIMENTAL
Intervention: Oxycodone 4 mg (group O)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Fentanyl 50 μg (group F)
Number of subjects: 46